Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KY-0601
- Development stage
- Preclinical
- Lead developer
- Novatim Immune Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KY-0601 is a first-in-class bispecific antibody-drug conjugate (ADC) developed by Novatim Immune Therapeutics. It is designed to simultaneously target two tumor-associated antigens, B7-H3 (CD276) and c-MET (hepatocyte growth factor receptor), which are frequently overexpressed in various malignancies including colorectal and esophageal cancers. The molecule utilizes a nanobispecific architecture and features a dual-toxin payload system intended to enhance therapeutic efficacy and potentially overcome resistance mechanisms associated with single-target therapies. KY-0601 is currently in the preclinical and CMC (Chemistry, Manufacturing, and Controls) development stage.
02
Targets
B7-H3MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on KY-0601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KY-0601.